Dioxopromethazine hydrochlorideCAS# 15374-15-9 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 15374-15-9 | SDF | Download SDF |
| PubChem ID | 11416891 | Appearance | Powder |
| Formula | C17H21ClN2O2S | M.Wt | 352.9 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 1-(5,5-dioxophenothiazin-10-yl)-N,N-dimethylpropan-2-amine;hydrochloride | ||
| SMILES | CC(CN1C2=CC=CC=C2S(=O)(=O)C3=CC=CC=C31)N(C)C.Cl | ||
| Standard InChIKey | LPDLZVGJDFEWFD-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C17H20N2O2S.ClH/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)22(20,21)17-11-7-5-9-15(17)19;/h4-11,13H,12H2,1-3H3;1H | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Dioxopromethazine hydrochloride Dilution Calculator
Dioxopromethazine hydrochloride Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.8337 mL | 14.1683 mL | 28.3366 mL | 56.6733 mL | 70.8416 mL |
| 5 mM | 0.5667 mL | 2.8337 mL | 5.6673 mL | 11.3347 mL | 14.1683 mL |
| 10 mM | 0.2834 mL | 1.4168 mL | 2.8337 mL | 5.6673 mL | 7.0842 mL |
| 50 mM | 0.0567 mL | 0.2834 mL | 0.5667 mL | 1.1335 mL | 1.4168 mL |
| 100 mM | 0.0283 mL | 0.1417 mL | 0.2834 mL | 0.5667 mL | 0.7084 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Eriodictyol-8-glucoside
Catalog No.:BCN8029
CAS No.:153733-96-1
- 9,10-Bis(3,5-dihydroxyphenyl)anthracene
Catalog No.:BCC8793
CAS No.:153715-08-3
- H-Ile-OEt.HCl
Catalog No.:BCC2961
CAS No.:15366-32-3
- Dofequidar fumarate
Catalog No.:BCC4177
CAS No.:153653-30-6
- GNE-9605
Catalog No.:BCC5458
CAS No.:1536200-31-3
- NS 1619
Catalog No.:BCC7779
CAS No.:153587-01-0
- 13-Hydroxylupanine
Catalog No.:BCN3204
CAS No.:15358-48-2
- DL-Menthol
Catalog No.:BCN5950
CAS No.:15356-70-4
- D-Menthol
Catalog No.:BCN4973
CAS No.:15356-60-2
- Bexarotene
Catalog No.:BCC3737
CAS No.:153559-49-0
- [D-Trp34]-Neuropeptide Y
Catalog No.:BCC7690
CAS No.:153549-84-9
- Cevimeline hydrochloride hemihydrate
Catalog No.:BCC1471
CAS No.:153504-70-2
- Fmoc-Trp-ol
Catalog No.:BCC2573
CAS No.:153815-60-2
- BLU9931
Catalog No.:BCC3979
CAS No.:1538604-68-0
- Boc-Gln-ONp
Catalog No.:BCC3383
CAS No.:15387-45-8
- NBOH-2C-CN hydrochloride
Catalog No.:BCC8025
CAS No.:1539266-32-4
- p-Hydroxyphenethyl vanillate
Catalog No.:BCN7555
CAS No.:1539303-03-1
- ANQ 11125
Catalog No.:BCC6359
CAS No.:153966-48-4
- 2-Deoxy-D-glucose
Catalog No.:BCC4048
CAS No.:154-17-6
- Lincomycin
Catalog No.:BCC9010
CAS No.:154-21-2
- Catechin
Catalog No.:BCN1688
CAS No.:154-23-4
- Thioguanine
Catalog No.:BCC2220
CAS No.:154-42-7
- 1,5-Anhydro-D-glucitol
Catalog No.:BCN2234
CAS No.:154-58-5
- Primverin
Catalog No.:BCC8238
CAS No.:154-60-9
Preparation of a beta-Cyclodextrin-Based Open-Tubular Capillary Electrochromatography Column and Application for Enantioseparations of Ten Basic Drugs.[Pubmed:26771454]
PLoS One. 2016 Jan 15;11(1):e0146292.
An open-tubular capillary electrochromatography column was prepared by chemically immobilized beta-cyclodextrin modified gold nanoparticles onto new surface with the prederivatization of (3-mercaptopropyl)-trimethoxysilane. The synthesized nanoparticles and the prepared column were characterized by transmission electron microscopy, scanning electron microscopy, infrared spectroscopy and ultraviolet visible spectroscopy. When the column was employed as the chiral stationary phase, no enantioselectivity was observed for ten model basic drugs. So beta-cyclodextrin was added to the background electrolyte as chiral additive to expect a possible synergistic effect occurring and resulting in a better separation. Fortunately, significant improvement in enantioselectivity was obtained for ten pairs of drug enantiomers. Then, the effects of beta-cyclodextrin concentration and background electrolyte pH on the chiral separation were investigated. With the developed separation mode, all the enantiomers (except for venlafaxine) were baseline separated in resolutions of 4.49, 1.68, 1.88, 1.57, 2.52, 2.33, 3.24, 1.63 and 3.90 for zopiclone, chlorphenamine maleate, brompheniramine maleate, Dioxopromethazine hydrochloride, carvedilol, homatropine hydrobromide, homatropine methylbromide, venlafaxine, sibutramine hydrochloride and terbutaline sulfate, respectively. Further, the possible separation mechanism involved was discussed.
Combined use of ionic liquid and hydroxypropyl-beta-cyclodextrin for the enantioseparation of ten drugs by capillary electrophoresis.[Pubmed:23740623]
Chirality. 2013 Jul;25(7):409-14.
In the present study, hydroxypropyl-beta-cyclodextrin and an ionic liquid (1-ethyl-3-methylimidazolium-l-lactate) were used as additives in capillary electrophoresis for the enantioseparation of 10 analytes, including ofloxacin, propranolol hydrochloride, Dioxopromethazine hydrochloride, isoprenaline hydrochloride, chlorpheniramine maleate, liarozole, tropicamide, amlodipine benzenesulfonate, brompheniramine maleate, and homatropine methylbromide. The effects of ionic liquid concentrations, salt effect, cations, and anions of ionic liquids on enantioseparation were investigated and the results proved that there was a synergistic effect between hydroxypropyl-beta-cyclodextrin and the ionic liquid, and the cationic part of the ionic liquid played an important role in the increased resolution. With the developed dual system, all the enantiomers of 10 analytes were well separated in resolutions of 5.35, 1.76, 1.85, 2.48, 2.88, 1.43, 5.45, 4.35, 2.76, and 2.98, respectively. In addition, the proposed method was applied to the determination of the enantiomeric purity of S-ofloxacin after validation of the method in terms of selectivity, repeatability, linearity range, accuracy, precision, limit of detection (LOD), and limit of quality (LOQ).
Combined use of ionic liquid and beta-CD for enantioseparation of 12 pharmaceuticals using CE.[Pubmed:23303483]
J Sep Sci. 2013 Feb;36(3):517-23.
In this study, the enantioseparation of zopiclone, repaglinide, chlorphenamine maleate, brompheniramine maleate, Dioxopromethazine hydrochloride, promethazine hydrochloride, liarozole, carvedilol, homatropine hydrobromide, homatropine methylbromide, venlafaxine, and sibutramine hydrochloride has been investigated using beta-CD in combination with a chiral ionic liquid (IL), 1-ethyl-3-methylimidazolium-L-lactate. The influence of the type of IL and its concentration, BGE pH, and chain length of the IL cations on the resolution are discussed. Finally, the proposed method was successfully applied for the chiral impurity determination of eszopiclone in pharmaceutical tablets after validation with respect to accuracy and precision, linearity range, selectivity, repeatability, LOD and LOQ. It is assessed that the chiral impurity determination in the commercial tables is fewer than 0.1%.
Spectroscopic investigation on the synergistic effects of ultrasound and dioxopromethazine hydrochloride on protein.[Pubmed:21424802]
J Fluoresc. 2011 Sep;21(5):1847-56.
The bovine serum albumin (BSA) was selected as a target molecule, the sonodynamic damage to protein in the presence of Dioxopromethazine hydrochloride (DPZ) and its mechanism were studied by means of absorption and fluorescence spectra. The results of hyperchromic effect of absorption spectra and quenching of intrinsic fluorescence spectra indicated that the synergistic effects of ultrasound and DPZ could induce the damage of BSA molecules. The damage degree of BSA molecules increased with the increase of ultrasonic irradiation time and DPZ concentration. The results of synchronous fluorescence and three-dimensional fluorescence spectra further confirmed that the synergistic effects of ultrasound and DPZ induced the damage of BSA molecules. The results of oxidation-extraction photometry with several reactive oxygen species (ROS) scavengers indicated that the damage of BSA molecules could be mainly due to the generation of ROS, in which both (1)O(2) and .OH were the important mediators of the ultrasound-inducing BSA molecules damage in the presence of DPZ.
Dioxopromethazine-induced photoallergic contact dermatitis followed by persistent light reaction.[Pubmed:9744913]
Am J Contact Dermat. 1998 Sep;9(3):182-7.
BACKGROUND: Although photosensitivity after photoallergy to topical phenothiazine antihistamines is well known, there have been no previous reports of dioxopromethazine inducing this phenomenon. OBJECTIVE: A housewife used 0.5% dioxopromethazine in Prothanon gel for palpebral pruritus and developed severe dermatitis of the lower eyelids with spread to the sun-exposed areas. METHODS: The minimal erythema doses and the minimal infiltrate doses for ultraviolet A (UVA) and ultraviolet B (UVB) were established before photopatch testing and at intervals up to 497 days thereafter. Test sites were read up to 144 hours after irradiation. Photopatch testing was performed with Prothanon gel, Dioxopromethazine hydrochloride 0.001% to 0.5%, and the standard photopatch test tray (Hermal/Trolab). For patch testing, various series of the German Contact Dermatitis Group were applied. RESULTS: Minimal erythema doses for UVA were diminished before photopatch testing and at intervals up to 500 days after Prothanon gel was discontinued. Exposure to UVB provoked abnormal delayed infiltrated reactions. Clinically the photosensitivity persisted within this period. Photoallergic reactions were seen with Prothanon gel, Dioxopromethazine hydrochloride 0.005% to 1.0%, and promethazine hydrochloride 0.1%. The patient gave positive patch test reactions to various fragrance materials, balsam of Peru, costus oil, and propylene glycol. CONCLUSION: Because topical dioxopromethazine may cause photoallergic contact dermatitis followed by long-lasting photosensitivity even after contact has been discontinued, its withdrawal from the market is recommended.
